Shots:

• Shionogi to receive $30M upfront ($20M as initial payment & additional $10M in 6mos.) and royalties based on the sales of Symproic. BDSI to get exclusive commercialization rights for Shionogi’s Symproic (naldemedine- 0.2mg) in the US and Puerto Rico
• The focus of the agreement is to strengthen the BDSI’s portfolio with expected company’s net sales $92-$100M and combined net sales of Belbuca and Symproic expected to be $325-$400M in H2’19
• Symproic (naldemedine- 0.2mg) is indicated for opioid-induced constipation (OIC) in adults- being evaluated in seven P-III clinical studies and has received highest category of endorsement from the American Gastroenterological Association in patients with laxative-refractory OIC

Ref: BioDelivery | Image: WSJ